BALYASNY ASSET MANAGEMENT L.P. - CTI BIOPHARMA CORP ownership

CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 133 filers reported holding CTI BIOPHARMA CORP in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.

Quarter-by-quarter ownership
BALYASNY ASSET MANAGEMENT L.P. ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q4 2022$5,237,168
+757.1%
871,409
+751.5%
0.01%
+600.0%
Q2 2022$611,000
+196.6%
102,333
+131.9%
0.00%
+100.0%
Q1 2022$206,000
-2.8%
44,136
-79.8%
0.00%0.0%
Q1 2019$212,000
-68.7%
218,273
-76.3%
0.00%
-80.0%
Q4 2018$677,000
+4.5%
922,655
+207.6%
0.01%
+66.7%
Q3 2018$648,000
-58.4%
300,000
-4.1%
0.00%
-57.1%
Q2 2018$1,558,000312,9160.01%
Other shareholders
CTI BIOPHARMA CORP shareholders Q1 2023
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 8,800,358$21,825,00010.02%
CAXTON CORP 2,239,300$5,553,0004.54%
Altium Capital Management LP 2,185,000$5,419,0001.49%
SILVERARC CAPITAL MANAGEMENT, LLC 1,483,829$3,680,0001.49%
Ghost Tree Capital, LLC 1,200,000$2,976,0001.07%
Lion Point Capital, LP 1,223,595$3,034,0000.81%
BVF INC/IL 8,929,690$22,146,0000.80%
NEA Management Company, LLC 7,140,450$17,708,0000.36%
Knott David M Jr 221,079$548,0000.19%
Lakeside Advisors, INC. 97,780$242,0000.18%
View complete list of CTI BIOPHARMA CORP shareholders